FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245951817> ?p ?o ?g. }

• W4245951817 endingPage "187" @default.
• W4245951817 startingPage "178" @default.
• W4245951817 abstract "BACKGROUND Clinical data clearly indicate a correlation between tumor neovascularization, aggressiveness of tumor growth, and metastatic spread. One of the key factors capable of stimulating tumor angiogenesis is vascular endothelial growth factor (VEGF). Using an immunoassay for VEGF, we assessed the levels of soluble VEGF in the sera and effusions of patients with malignant and nonmalignant disease as well as in the sera of healthy controls. METHODS Using a sandwich enzyme-linked immunoadsorbent assay, the concentration of VEGF was measured in serum specimens (n = 445) and effusions (n = 56) collected from a total of 212 patients with various types of cancer, 88 patients with nonmalignant disease, and 145 healthy individuals. RESULTS Low and rather stable levels of VEGF were detected in the serum of healthy individuals (median, 294 pg/mL; range, 30–1752 pg/mL; 95th percentile, 883 pg/mL). Compared with healthy individuals, serum levels in patients with acute infections were elevated (P = 0.03), whereas patients with chronic cirrhosis had lower serum VEGF levels. Among patients with various types of neoplasia, VEGF serum levels in patients with ovarian or gastrointestinal carcinoma were significantly higher than in healthy individuals. Moreover, VEGF concentrations in sera from patients with metastatic disease were higher than in sera from patients with localized tumors. Maximum serum concentrations of VEGF (median, 1022 pg/mL; range, 349–7821 pg/mL) were found in patients with metastatic ovarian carcinoma. Median VEGF levels (and ranges) in malignant effusions were up to 10-fold higher than in matched serum samples: 5528 pg/mL (468–49269 pg/mL) in ovarian carcinoma, 885 pg/mL (77–14,337 pg/mL) in breast carcinoma, and 813 pg/mL (372–18,331 pg/mL) in gastrointestinal carcinoma. In contrast, ascitic fluid from patients with cirrhosis contained only 303 pg/mL (median, range 116–676 pg/mL) of VEGF, corresponding to the low serum levels in this patient group. CONCLUSIONS Depending on the tumor type, elevated levels of VEGF are detectable in the serum of only 0–20% of patients with localized cancer but in 11–65% of patients with metastatic cancer. Of cytology-proven malignant ascites or peritoneal exudates from various malignancies, 46–96% show VEGF levels above the upper limit (95th percentile, 676 pg/mL) of nonmalignant ascites. Maximum VEGF concentrations in malignant effusions indicate abundant local release of VEGF within the pleural or peritoneal cavity. These results suggest that VEGF might play an important role in tumor progression and the formation of malignant effusions. Further studies are warranted to determine the clinical value of soluble VEGF as a tumor marker, a prognostic factor, and a surrogate indicator of tumor angiogenesis. Cancer 1999;85:178–87. © 1999 American Cancer Society." @default.
• W4245951817 created "2022-05-12" @default.
• W4245951817 creator A5011907623 @default.
• W4245951817 creator A5012279185 @default.
• W4245951817 creator A5013627281 @default.
• W4245951817 creator A5017948816 @default.
• W4245951817 creator A5019066306 @default.
• W4245951817 creator A5025153159 @default.
• W4245951817 creator A5034695241 @default.
• W4245951817 creator A5042277242 @default.
• W4245951817 creator A5064684263 @default.
• W4245951817 date "1999-01-01" @default.
• W4245951817 modified "2023-10-16" @default.
• W4245951817 title "Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease" @default.
• W4245951817 doi "https://doi.org/10.1002/(sici)1097-0142(19990101)85:1<178::aid-cncr25>3.3.co;2-z" @default.
• W4245951817 hasPublicationYear "1999" @default.
• W4245951817 type Work @default.
• W4245951817 citedByCount "8" @default.
• W4245951817 crossrefType "journal-article" @default.
• W4245951817 hasAuthorship W4245951817A5011907623 @default.
• W4245951817 hasAuthorship W4245951817A5012279185 @default.
• W4245951817 hasAuthorship W4245951817A5013627281 @default.
• W4245951817 hasAuthorship W4245951817A5017948816 @default.
• W4245951817 hasAuthorship W4245951817A5019066306 @default.
• W4245951817 hasAuthorship W4245951817A5025153159 @default.
• W4245951817 hasAuthorship W4245951817A5034695241 @default.
• W4245951817 hasAuthorship W4245951817A5042277242 @default.
• W4245951817 hasAuthorship W4245951817A5064684263 @default.
• W4245951817 hasConcept C121608353 @default.
• W4245951817 hasConcept C126322002 @default.
• W4245951817 hasConcept C142724271 @default.
• W4245951817 hasConcept C167734588 @default.
• W4245951817 hasConcept C2777025900 @default.
• W4245951817 hasConcept C2777214474 @default.
• W4245951817 hasConcept C2778271429 @default.
• W4245951817 hasConcept C2780394083 @default.
• W4245951817 hasConcept C71924100 @default.
• W4245951817 hasConcept C90924648 @default.
• W4245951817 hasConceptScore W4245951817C121608353 @default.
• W4245951817 hasConceptScore W4245951817C126322002 @default.
• W4245951817 hasConceptScore W4245951817C142724271 @default.
• W4245951817 hasConceptScore W4245951817C167734588 @default.
• W4245951817 hasConceptScore W4245951817C2777025900 @default.
• W4245951817 hasConceptScore W4245951817C2777214474 @default.
• W4245951817 hasConceptScore W4245951817C2778271429 @default.
• W4245951817 hasConceptScore W4245951817C2780394083 @default.
• W4245951817 hasConceptScore W4245951817C71924100 @default.
• W4245951817 hasConceptScore W4245951817C90924648 @default.
• W4245951817 hasIssue "1" @default.
• W4245951817 hasLocation W42459518171 @default.
• W4245951817 hasOpenAccess W4245951817 @default.
• W4245951817 hasPrimaryLocation W42459518171 @default.
• W4245951817 hasRelatedWork W1978071930 @default.
• W4245951817 hasRelatedWork W2049739326 @default.
• W4245951817 hasRelatedWork W2101492103 @default.
• W4245951817 hasRelatedWork W2140167336 @default.
• W4245951817 hasRelatedWork W2163645502 @default.
• W4245951817 hasRelatedWork W2184820196 @default.
• W4245951817 hasRelatedWork W2357156918 @default.
• W4245951817 hasRelatedWork W2369484006 @default.
• W4245951817 hasRelatedWork W3029520671 @default.
• W4245951817 hasRelatedWork W3031894719 @default.
• W4245951817 hasVolume "85" @default.
• W4245951817 isParatext "false" @default.
• W4245951817 isRetracted "false" @default.
• W4245951817 workType "article" @default.